Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
New hope for treating devastating brain cancer in children

New hope for treating devastating brain cancer in children

Protein discovery opens door for new options in diagnosis and therapy of cancer

Protein discovery opens door for new options in diagnosis and therapy of cancer

Research reveals genomic basis of acute erythroid leukemia

Research reveals genomic basis of acute erythroid leukemia

Heating tumors during CAR T-cell therapy can enhance treatment's success, study suggests

Heating tumors during CAR T-cell therapy can enhance treatment's success, study suggests

Prostate cancer cells 'spit out' a protein that promotes tumor growth

Prostate cancer cells 'spit out' a protein that promotes tumor growth

Immune system errors linked to development of childhood leukemia

Immune system errors linked to development of childhood leukemia

Understanding maintenance of quiescent stem cells in chronic myelogenous leukemia

Understanding maintenance of quiescent stem cells in chronic myelogenous leukemia

City of Hope receives $7.5 million in grant awards to study cutaneous T cell lymphoma

City of Hope receives $7.5 million in grant awards to study cutaneous T cell lymphoma

Chemistry researchers patent new method for making anti-leukemia compounds

Chemistry researchers patent new method for making anti-leukemia compounds

New Australian drug trial achieves remarkable results in patients with acute myeloid leukemia

New Australian drug trial achieves remarkable results in patients with acute myeloid leukemia

FDA warns marketer of unapproved products claiming to treat addiction, chronic pain

FDA warns marketer of unapproved products claiming to treat addiction, chronic pain

Antibody-drug conjugate effectively targets surface protein in childhood neuroblastomas

Antibody-drug conjugate effectively targets surface protein in childhood neuroblastomas

Study reveals how a regulatory molecule ensures appropriate supply of blood cells

Study reveals how a regulatory molecule ensures appropriate supply of blood cells

Scientists find highly promising therapeutic target for leukemia

Scientists find highly promising therapeutic target for leukemia

Study unravels how cancer medication works in brains of Parkinson's patients

Study unravels how cancer medication works in brains of Parkinson's patients

Novel biosensor can isolate and target leukemic stem cells

Novel biosensor can isolate and target leukemic stem cells

A molecular epigenetic marker can predict survival of children with leukemia

A molecular epigenetic marker can predict survival of children with leukemia

Almost half of all childhood cancer cases go undiagnosed

Almost half of all childhood cancer cases go undiagnosed

New test could be a ‘game changer’ in the treatment of chronic lymphocytic leukemia

New test could be a ‘game changer’ in the treatment of chronic lymphocytic leukemia

Killer T cells may explain inability of immune cells to destroy cancer tumors

Killer T cells may explain inability of immune cells to destroy cancer tumors

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.